Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OP-724 dose-escalation in primary biliary cholangitis (Phase I)
jRCT2031190073Phase 1Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of foscenvivint in primary biliary cholangitis (PBC), sponsored by Japan Agency for Medical Research and Development. Started Sep 2019; status: completed.
02
Drugs
foscenvivint
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on jRCT2031190073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190073.